Roivant Sciences Ltd.

Roivant Sciences Ltd. is a biopharmaceutical company focused on developing and commercializing medicines. The company's pipeline includes several product candidates. Brepocitinib, a small molecule inhibitor of JAK1 and TYK2, is currently under review at the FDA for dermatomyositis with a PDUFA Date of 3Q 2026. It is also in Phase 3 development for non-infectious uveitis and cutaneous sarcoidosis, and in Phase 2b/3 development for lichen planopilaris, all under the subsidiary Priovant. IMVT-1402, a fully human monoclonal antibody targeting FcRn, is in development across several IgG-mediated autoimmune indications under the subsidiary Immunovant. These include Phase 2/3 trials for Difficult-to-Treat Rheumatoid Arthritis, Graves' Disease, Myasthenia Gravis, Chronic Inflammatory Demyelinating Polyneuropathy, and Sjögren's Disease, as well as a Phase 2 trial for Cutaneous Lupus Erythematosus. Mosliciguat, an inhaled sGC activator, is in Phase 2 development for pulmonary hypertension associated with interstitial lung disease under the subsidiary Pulmovant. Roivant advances its pipeline by creating subsidiaries, referred to as "Vants," to develop and commercialize its medicines and technologies. Beyond therapeutics, Roivant also incubates discovery-stage companies and health technology startups that complement its biopharmaceutical business.